Donna Cochener - 14 Mar 2022 Form 4 Insider Report for Neoleukin Therapeutics, Inc. (NGNE)

Role
General Counsel, SVP Legal
Signature
/s/ Sean Smith, as Attorney-in-Fact for Donna Cochener
Issuer symbol
NGNE
Transactions as of
14 Mar 2022
Net transactions value
$0
Form type
4
Filing time
15 Mar 2022, 18:05:00 UTC
Next filing
04 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NLTX Stock Option (Right to Buy) Award $0 +400,000 $0.000000 400,000 14 Mar 2022 Common Stock 400,000 $1.81 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 1/4 of the total shares on March 14, 2023, and then 1/48 of the total shares will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.